

A2  
A3  
A4  
3. (Amended) Process according to claim 2 in which the enzyme is one in which amino acid 47 or 51 or 47 and 51 of P450<sub>BM-3</sub>, or amino acid 96 of P450<sub>cam</sub>, or the equivalent amino acid in a said homologue, have been changed to an amino acid with a less polar side-chain.

6. (Amended) The enzyme as defined in claim 4 excluding mutants of P450<sub>cam</sub> which only have the mutations F87A-Y96G-F193A, F87A-Y96G-F193A-C334A, or T101M-T185F-V247M.

8. (Amended) A cell which expresses:

- (i) a mutant haem-containing enzyme comprising a substitution of an amino acid in an active site by an amino acid with a less polar side-chain which in its naturally occurring form has an electron transfer reductase domain, or
- (ii) (a) a mutant haem-containing enzyme comprising a substitution of an amino acid in an active site by an amino acid with a less polar side-chain,
- (b) an electron transfer reductase, and
- (c) an electron transfer redoxin; or
- (iii) (a) (1) P450<sub>cam</sub> or a fragment thereof; or
- (2) a naturally occurring homologue of P450<sub>cam</sub> or a fragment thereof; or
- (3) a mutant P450<sub>cam</sub>, or a mutant of a naturally occurring homologue of P450<sub>cam</sub> comprising a substitution of an amino acid in an active site by an amino acid with a less polar side-chain; or
- (4) a P450<sub>cam</sub> which has at least 70% amino acid homology with (1), (2) or (3) and optionally in which amino acid 96 has been changed to an amino acid with a less polar side-chain; and
- (b) an electron transfer reductase; and

(c) an electron transfer redoxin, of

(iv) (a) (1) P450<sub>BM-3</sub>, or a fragment thereof; or

(2) a naturally occurring homologue of P450<sub>BM-3</sub> or a fragment thereof; or

(3) a mutant P450<sub>BM-3</sub> or a mutant of a naturally occurring homologue of P450<sub>BM-3</sub> comprising a substitution of an amino acid in an active site by an amino acid with a less polar side-chain

excluding an *E. Coli* DH5 $\alpha$  cell in which the only mutants of P450<sub>cam</sub> which are expressed are amongst the following:

H<sub>2</sub>N-P450<sub>cam</sub>-TDGTSST-putidaredoxin reductase-TDGASSS-putidaredoxin-COOH,

H<sub>2</sub>N-P450<sub>cam</sub>-TDGTRPGPGPGGPSST-putidaredoxin reductase-TDGASSS-putidaredoxin-COOH,

H<sub>2</sub>N-P450<sub>cam</sub>-TDGTRPGPGPGPGGPSST-putidaredoxin reductase-TDGASSS putidaredoxin-COOH,

H<sub>2</sub>N-450<sub>cam</sub>-putidaredoxin reductase-TDGASSS-putidaredoxin-PLEL-P450<sub>cam</sub>-COOH.

9. (Amended) The cell according to claim 8 in which (a), (b) and (c) or (b) and (c) are expressed together in the same fusion protein.

10. (Amended) The cell according to claim 8 in which:

(b) is putidaredoxin reductase or a fragment thereof; and/or

(c) is putidaredoxin or a fragment thereof.

11. (Amended) Process for oxidising a substrate which is an acyclic or cyclic terpene, or a cycloalkene, or a substituted derivative thereof, and which process comprises oxidising said substrate with a mutant haem-containing enzyme, the mutant comprising a substitution of a first amino acid in an active site by an amino acid with a less polar side-chain, wherein the substrate is oxidised in a cell according to claim 8.

13. (Amended) Process for selecting a mutant of P450<sub>cam</sub> or P450<sub>BM-3</sub>, or a homologue thereof, for its ability to oxidise a substrate, which process comprises screening a group of said mutants for their oxidation effect on the substrate.

14. (Amended) Process according to claim 13 in which the mutant is additionally selected for its ability to oxidise the substrate to an oxidation product.

15. (Amended) Process for selecting a mutant of P450<sub>cam</sub> or P450<sub>BM-3</sub>, or a homologue thereof, for its ability to oxidise a substrate, which process comprises screening a group of said mutants for their oxidation effect on the substrate in which the screening is carried out on the library made in a process according to claim 12.

16. (Amended) A process for producing a library of oxidation products comprising providing an acyclic or cyclic terpene, or a cycloalkene, or a substituted derivative thereof to a library made in a process according to claim 12 and allowing oxidation of the substrate.

17. (Amended) A method of treatment of a human or an animal comprising administering an oxidation product obtained by oxidising a substrate which is an acyclic or cyclic terpene, or a cycloalkene, or a substituted derivative thereof, and which process comprises oxidising said substrate with a mutant haem-containing enzyme, the mutant comprising a substitution of an amino acid in an active site by an amino acid with a less polar side-chain, wherein optionally the enzyme is one which has been selected in a process according to claim 13.

18. (Amended) A pharmaceutical composition comprising an oxidation product obtained by oxidising a substrate which is an acyclic or a cyclic terpene, or a cycloalkene, or a substituted derivative thereof, and which process comprises oxidising said substrate with a mutant haem-containing enzyme, the mutant comprising a substitution of an amino acid in an active site by an amino acid with a less polar side-chain, wherein optionally the enzyme is one which has been selected in a process according to claim 13 and a pharmaceutically acceptable carrier or diluent.

09856339.001501